|Publication number||USRE38934 E1|
|Application number||US 10/375,340|
|Publication date||Jan 10, 2006|
|Filing date||Feb 27, 2003|
|Priority date||Oct 2, 1997|
|Also published as||CA2304970A1, CA2304970C, CN1193019C, CN1273581A, CN1699349A, DE69820895D1, DE69820895T2, DE69830860D1, DE69830860T2, EP1027339A1, EP1027339B1, EP1342718A1, EP1342718B1, US6093820, US6664262, US6906079, US20030018080, US20040167358, WO1999018084A1|
|Publication number||10375340, 375340, US RE38934 E1, US RE38934E1, US-E1-RE38934, USRE38934 E1, USRE38934E1|
|Inventors||Daniela Gutman, Hershel Herzog|
|Original Assignee||Taro Pharmaceutical Industries Ltd.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (10), Non-Patent Citations (24), Referenced by (28), Classifications (36), Legal Events (2)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The invention relates to a new means for N-alkylating ureides that is higher yielding, more convenient, and safer to use than techniques practiced heretofore. This approach is particularly suited to preparing N-(alkoxyalkylene) ureides, which include anti-convulsant drugs of the N-substituted barbituric acid class.
The term ureide is used in e.g. Foye, Principles of Medicinal Chemistry, 3d ed. (1990), pp. 164, 179, which is incorporated herein by reference. Ureides are a class of imides of general structure I:
Examples, include hypnotics, such as acecarbromal, apronalide, bromisolvalum, capuride, carbromal, and ectylurea; and anticonvulsant drugs such as hydantoins, glutarimides, oxazolidinediones, succinimides, and barbiturates such as barbituric acid (structure II).
U.S. Pat. No. 4,628,056 teaches a method of making 1,3 bis(methoxymethyl)-5,5-diphenyl barbituric acid (also called (N,N′-bis(methoxymethyl)-5,5-diphenyl barbituric acid) by dissolving diphenyl barbituric acid in cooled dimethylformamide, adding sodium hydride, then adding chloromethyl methyl ether. Chloromethyl methyl ether has been widely used to alkylate with a methoxymethylene function. However, it is highly toxic and regulated as a carcinogen. It is extremely volatile and flammable under exothermic reaction conditions, and alternatives to its use are strongly desirable.
Almost three decades ago, methoxymethyl methanesulfonate was identified as an agent for alkylating some alcohols and amines in a self-catalyzing reaction. Karger et al., J.A.C.S. 91:5663 (1969). With amines, the reaction was complex and led to salts, dimers, and other side products being formed. This method has not been applied to alkylation of ureides, or imides, for which there are major differences in electron availability at nitrogen.
The invention method avoids the use of volatile, carcinogenic chloromethyl methyl ether, replacing that reagent with a more reactive, less volatile alternative which may be generated in situ (without risk to the operator).
The invention solves a previously unrecognized problem limiting the applicability of methoxymethanesulfante alkylation to alcohols and amines. Ureides are much less basic than amines, so a different method for oxyalkylation is required. This invention differs from the method of Karger et al. by using a ureide, a non-aqueous basic catalyst, and an aprotic solvent, modifications which were not previously known or suggested. The inventive method allows use of a variety of sulfonates to prepare a broad variety of oxyalkylated ureides, some not previously known. The simplicity and convenience of the invention provide advantages that were not previously appreciated.
A method of N-alkoxyalkylating ureides according to the invention comprises reacting a ureide of structure I with an alkylating agent of structure III in the presence of a basic catalyst in an aprotic reaction medium. The alkylating agent III may be combined directly with the ureide, or the method may include reacting in situ a mixed anhydride of acetic acid and a sulfonic acid with a dialkoxymethane to provide the alkylating agent III. The method preferably involves isolating the resultant N-alkoxyalkylated ureide.
Preferably, the ureide is a 5,5-disubstituted barbituric acid, phenytoin, glutethimide, or ethosuximide. The alkylating agent may be methoxymethyl methanesulfonate, methoxymethyl benzenesulfonate, or methoxymethyl p-toluenesulfonate. The base may be selected from sodium hydride, triethyl amine, and di-isopropyl ethyl amine.
When the process includes the step of reacting a dialkoxymethane and a mixed acetic sulfonic anhyride to produce the resulting ester of the sulfonic acid, that reaction may be carried out in the same vessel as the following reaction with the ureide (done sequentially).
A preferred process comprises N-alkylating 5,5-diphenyl-barbituric acid with a reagent selected from the group consisting of methoxymethyl methanesulfonate, methoxymethyl benzenesulfonate, and methoxymethyl p-toluenesulfonate, in the presence of di-isopropyl ethyl amine and isolating the resultant N,N′-bismethoxymethyl-5,5-diphenyl-barbituric acid.
The invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenyl-barbituric acid, N-methoxymethyl ethosuximide and N-methoxymethyl glutethimide, methods of making them, and a method comprising administering to a patient an effective amount of a pharmaceutical agent selected from the group consisting of N-methoxymethyl-5,5-diphenyl-barbituric acid, N-methoxymethyl ethosuximide and N-methoxymethyl glutethimide.
Further objectives and advantages will become apparent from a consideration of the description and examples.
PREFERRED EMBODIMENTS In describing preferred embodiments of the present invention illustrated in the drawings, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected, and it is to be understood that each specific element includes all technical equivalents which operate in a similar manner to accomplish a similar purpose.
The reagent class which possesses the desirable N-alkylating properties is characterized as compounds of structure III
where the R groups are preferably as follows:
TABLE 1 Compound III R3 R4 R5 1. methoxymethyl methanesulfonate H H CH3 2. ethoxymethyl methanesulfonate CH3 H CH3 3. benzyloxymethyl methanesulfonate phenyl H CH3 4. methoxymethyl ethanesulfonate H H C2H3 5. methoxymethyl benzenesulfonate H H phenyl 6. methoxymethyl ρ-toluenesulfonate H H tolyl 7. methoxybenzylidene methanesulfonate H phenyl CH3 8. methoxyethylidene methanesulfonate H CH3 CH3
A particularly preferred reagent is methoxymethyl methanesulfonate.
The ureides which have been shown to be alkylated belong to the family of compounds having structure I:
which may be linear (with R1 and R2 being alkyl, aryl, or arylakyl), or cyclic (R1 and R2 bonded to form a ring). Tables 2 and 3 (taken from Foye et al., Principles of Medicinal Chemistry, 3rd Edition (Lea and Febiger 1990), pp.164 and 179) depict ureide drugs.
Structure of Anticonvulsant Drugs Containing the Ureide Structure
Class of Compounds
TABLE 3 Ureide Hypnotics General Structure Generic Name Chemical Name R1 R2 Acecarbromal (1-acetyl)-2-(2- bromo-2-ethylbutyryl) urea CH3CO Aprohalide (2-isopropyl-4- pentencyl)urea H Bromisovalum (2-bromo-3-methyl- butyryl)urea H Capuride (2-ethyl-3-methyl- valeryl)urea H Carbromal (2-bromo-2-ethyl- butyryl)urea H Ectylurea (2-ethyl-cis- crulonoyl)urea H
Examples of these ureides include those listed above and:
The preferred family of reactant ureides is the barbituric acids dissolving at 5, as in structure IV with the R groups preferably being the same or different alkyl or aryl groups, and most preferably with both R groups being phenyl.
Analogous products resulting from the process of the invention, where 5,5-diphenyl-barbituric acid is a substrate, include:
The N-methoxymethyl derivative of 5,5-diphenylbarbituric acid (Formula IX) may be prepared by the process of this invention.
The substrate 5,5-diphenylbarbituric acid is converted to its di-anion salt with a very strong base (as strong as a hydride, e.g. NaH) and then one equivalent is added of the alkoxy-alkylating agent, reagent 1 of Table 1. N-methoxymethyl-5,5-diphenylbarbituric acid is obtained by optimizing the reaction to favor monosubstitution. For example, an excess of the very strong base NaH is used, greater than two molar equivalents per mole of the ureide. The monosubstituted product is separated by chromatography or other conventional methods and may be characterized by melting point and nuclear magnetic resonance.
Pharmaceutically-effective salts of the alkylated ureides are also contemplated within the scope of the invention.
In general, stoichiometric amounts of the components are used. That is, for mono-alkylation, the ratio of ureide:alkylating agent:base is about 1:1:2; for di-substitution, the ratio is about 1:2:2, and so on. Different ratios may be appropriate depending on the reaction conditions. A person of ordinary skill will recognize that by varying these ratios, the reaction may proceed faster or slower and have higher or lower yield of end products. For example, as discussed above, mono-substitution of a ureide of the barbituric acid family is favored by using excess base.
For the reaction to proceed a non-aqueous basic catalyst is required. The base may be as strong as sodium hydride or as weak as a tertiary amine. For disubstituted products, the basic catalyst is preferably an amine that does not compete with the substrate ureide (or imide). To this end primary and secondary amine catalysts are excluded. Tertiary amines, which react more slowly with the alkylating species, are preferred to minimize the competing reaction through steric hindrance (branching in the amine substituents). Especially preferred for this attribute are highly hindered amines, such as the readily available amine, ethyl di-isopropyl amine. The hindrance inhibits quarternization of the catalyst amine by the alkylating agent in competition with the ureide substrate, while not interfering significantly with ability of the amine to act as a base (accept a proton). Useful bases include sodium hydride, potassium hydride, lithium hydride, triethylamine, tri-n-propylamine, and di-isopropyl ethyl amine.
The solvent is chosen so as not to compete with the substrate and to maximize the rate of alkylation. The use of dipolar aprotic solvents such as dimethyl formamide, dimethyl sulfoxide, dimethylacetamide, sulfolane, N-methylpyrrolidione, etc., appears to optimize these attributes. Otherwise, any dipolar aprotic solvent may be selected by the person of ordinary skill so long as the solvent is capable of bringing the reactants into solution. The preferred temperature range for the alkylation process is at or near ambient temperature (25±5° C.). Higher temperatures tend to stimulate competitive side-reactions between the alkylating agent and the tertiary amine catalyst (where the latter is being used).
Yields according to the invention are at least as high as with prior art methods. The high yields complement the other advantages of the inventive method including the facts that it is much safer, more convenient, and economical, and allows for ready synthesis of new compounds.
A preferred embodiment of the inventive alkylation process (which employs the preferred substrate and preferred reagent illustrated above) affords the N,N′ disubstituted barbituric acid depicted as structure V where the R groups are phenyl.
The alkylation preferably takes place in a solvent which is usually a dipolar aprotic solvent like an N,N′-dialkylamide. However, other types of aprotic solvents may also be employed, so long as they are compatible with the base. This alkylating technique is particularly novel and convenient in that the active alkylating species may also be generated in situ by employing precursor substances without isolation of the sulfonate reagent itself. Thus, dimethoxymethane (structure VI) may be reacted with the mixed anhydride of acetic and methanesulfonic acids (structure VII) and the resulting in situ generated sulfonate ester, methoxymethyl methanesulfonate (structure VIII, which is structure III where R3=H, R4=H, and R5=CH3) may be applied without isolation or purification to the N-alkylation of the barbituric acid.
The following examples are intended to illustrate various embodiments of the invention without limiting its scope.
A. Using a Hindered Tertiary Amine Catalyst
Dimethoxymethane (10.85 g) was added at 0° C. to 19.7 g of acetylmethanesulfonate. The reaction was stirred at 25° C. for 2 hours. The resultant solution was then added gradually over 45 minutes to a mixture of 10 g of 5,5-diphenylbarbituric acid and 13.85 g of N,N-diisopropyl ethyl amine in 60 ml of dry dimethylformamide. The resultant reaction mixture was stirred for about 15 minutes and then diluted with 180 ml of 2 N HCl, followed by 300 ml of ethyl acetate. The phases were separated and the ethyl acetate phase was washed first with 150 ml of saturated aqueous sodium chloride and then with 150 ml of 2N aqueous NaOH. The organic (ethyl acetate) phase was dried over anhydrous sodium sulfate, filtered and concentrated to dryness to give 12.2 g of N,N′-bismethoxymethyl-5,5-diphenylbarbituric acid. Crystalization from 48 ml of toluene afforded 10.5 g of pure product (79.6% yield).
B. Using Triethylamine as Catalyst
By the procedure of example A, using 10.84 g, of triethylamine (in place of 13.85 g of diisopropylethylamine), there resulted 10.62 g of crude alkylated product. Crystallization from 40 ml of toluene afforded 7.6 g (58.5%) of N,N′-bismethoxymethyl 5,5-diphenylbarbituric acid.
C. Using Sodium Hydride as Catalyst
By the procedure of example A, using 3.57 g of sodium hydride (60% dispersion in mineral oil) in place of the amine catalyst, there resulted after crystallization from toluene 5.0 g (38%) of N,N′-bismethoxymethyl-5,5-diphenylbarbituric acid.
D. Using Acetylbenzenesulfonate in place of acetylmethanesulfonate
By the procedure of example A, using 28.55 g of acetylbenzenesulfonate in place of acetylmethanesulfonate (19.7 g), the pure alkylated product resulted in 75.5% yield.
Completion of the reaction may be checked using conventional methods such as by TLC on silica (mobile phase chloroform methanol 98:2). The reaction mixture is diluted with 360 ml of water and extracted with 480 ml of ethyl acetate. The organic layer is separated and washed twice with 150 ml of water. The solvent is removed by distillation under reduced pressure in order to obtain crude product. The crude product may be purified by crystallization from 4 parts of toluene. The mixture is heated to reflux to dissolve and cooled to room temperature. According to HPLC the product of the inventive method has 98-100% purity, and yields of about 60-80% may be expected.
By the procedure of Example 1A, using diethoxymethane (15.42 g) in place of dimethoxymethane (10.85 g), there is obtained a 68% yield of pure N,N′-bismethoxymethyl-5,5-diphenylbarbituric acid.
By the procedure of 1A, using phenytoin (18 g) in place of 5,5-diphenylbarbituric acid (10 g), there is obtained a 70% yield of 3-methoxymethylphenytoin.
By the procedure of 1A, using glutethimide (15.5 g) in place of 5,5-diphenylbarbituric acid (10 g) there is obtained a 65% yield of N-methoxymethylglutethimide.
By the procedure of 1A, using ethosuximide (10 g) in place of 5,5-diphenylbarbituric acid (10 g), there is obtained a 60% yield of N-methoxymethylethosuximide.
The monosubstituted methoxymethyl derivative is obtained by optimizing the procedure of Example 1A to favor monosubstitution, using an excess of NaH and one equivalent of alkylating agent per equivalent of ureide. The monosubstituted product is separated and characterized.
The compounds of examples 2-6 have advantageous pharmaceutical properties over a sustained period of time. They may be used to treat mammals including humans for convulsions, seizures, muscle stiffness, nervous strain or anxiety, by administering an effective amount of the compound in a pharmaceutically acceptable carrier to the patient.
The embodiments illustrated and discussed in this specification are intended only to teach those skilled in the art the best way known to the inventors to make and use the invention. Nothing in this specification should be considered as limiting the scope of the present invention. Modifications and variations of the above-described embodiments of the invention are possible without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. It is therefore to be understood that, within the scope of the claims and their equivalents, the invention may be practiced otherwise than as specifically described.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2673205||Feb 4, 1952||Mar 23, 1954||Ciba Pharm Prod Inc||3-disubstituted dioxopiperidines and the manufacture thereof|
|US4628056 *||Sep 5, 1984||Dec 9, 1986||Taro Pharmaceutical Industries Ltd.||Novel oxopyrimidine derivatives, pharmaceutical compositions containing them and their use as anticonvulsant, antianxiety and muscle relaxant agents|
|US6184238||Dec 25, 1997||Feb 6, 2001||Nikken Chemicals Co., Ltd.||N-hydroxyurea derivative and pharmaceutical composition containing the same|
|US6372757||May 4, 1999||Apr 16, 2002||Smithkline Beecham P.L.C.||Phenylurea and phenylthio urea derivatives|
|US6664262||Feb 12, 2002||Dec 16, 2003||Taro Pharmaceuticals Industries Ltd.||N-methoxymethyl-5,5-diphenylbarbituric acid|
|DE2622981A1||May 21, 1976||Dec 8, 1977||Unisearch Ltd||(N)-Haloalkyl nitrogen-contg. heterocyclics prodn. - by reacting (N)-heterocyclics e.g. barbiturates with bis-haloalkyl sulphates, e.g. bis-chloroethyl sulphate|
|DE4028040A1||Sep 5, 1990||Mar 12, 1992||Chemie Linz Deutschland||N-Alkylation of urea cpds. - by reacting urea cpd. with alkylating agent in diluent in presence of phase transfer catalyst and solid base|
|EP1083172A1||May 26, 1998||Mar 14, 2001||Rimma Iliinichna Ashkinazi||N-substituted derivatives of 5-oxyiminobarbituric acid|
|WO2001079185A1||Apr 18, 2001||Oct 25, 2001||Kenneth Curry||Novel amino carboxy alkyl derivatives of barbituric acid|
|WO2002007729A1||Jul 26, 2001||Jan 31, 2002||Levitt Barrie||Non-sedating barbiturate compounds as neuroprotective agents|
|1||*||Aldrich Chemical Catalog, 1990-1991, p. 303.|
|2||Bhardwaj et al.: "Pentobarbital Inhibits extracellular release of dopamine in the Ischemic Striatum"; Journal of Neural Transmission [GenSect] (1990) 82; pp. 111-117.|
|3||Casara et al.: "Synthesis of Acid Stable Fluorinated Acyclonucleosides as Potential Antiviral Agents"; Tetrahedron Letters, vol. 32, No. 31, pp. 3823-3826, 1991.|
|4||*||Foye, "Principles of Medicinal Chemistry", 3rd ed., 1990, pp. 164, 179.|
|5||*||Groth et al., EP-726252, (1996) (Abstract only).|
|6||*||JP Gesson, JC Jacquesy, D. Rambaud, A practical method for N-alkylation of succinimide and glutarimide, Bulletin De La Societe Chimique De France, vol. 129, No. 3, 1992, pp. 227-231.|
|7||*||Karger et al., "Methoxymethyl Methanesulfonate, N Novel Active Oxyakylating Agent", Journal of the American Chemical Society, 91:5663 (1969).|
|8||Loudon et al: "Organic Chemistry"; Addison-Wesley (1984), pp. 617, 721-722, 1061-1064, 1086-1088, 1194.|
|9||Masuda et al.: "Relationships Between Plasma Concentrations of Diphenythydantoin, Phenobarbital, Carbamazepine, and 3-Sulfamoylmethyl-1,2-Benzisoxazole (AD-810), a New Anticonvulsant Agent, and Their Anticonvulsant or Neurotoxic Effects in Experimental Animals"; Epilepsia, vol. 20, December 1979, pp. 623-633.|
|10||McElvain: "5,5-Diphenylbarbituric Acid"; vol. 57, pp. 1303-1304, (1935).|
|11||*||P. Casara et al., Synthesis of acid stable fluorinated acylnacleosides, vol. 32, No. 31, 1991, pp. 3823-3826.|
|12||Raines, et al., "A Comparison of the Anticonvulsant, Neurotoxic and Lethal Effects of Diphenylbarbituric Acid Phenobarbital and Diphenylhydantoin in the Mouse," Journal of Pharmacology and Experimental Therapeutics, 186:315-322 (1973).|
|13||Raines, et al., "Conversion of Dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the Dog," The FASEB J., 13(4):A475,Ansract 394.2 (1999).|
|14||Raines, et al., "Conversion of Dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the Rat," The FASEB J., 10:A-155, Abstract 895 (1996).|
|15||Raines, et al., "Differential Selectivity of Several Barbiturates on Experimental Seizures and Neurotoxicity in the Mouse," Epilepsia, 20:105-113 (1979).|
|16||Raines, et al., "The Effects of 5,5-Diphenylbarbituric Acid on Experimental Seizures in Rats: Correlation Between Plasma and Brain Concentrations and Anticonvulsant Activity," Epilepsia,16:575-581 (1975).|
|17||Raines, et al.,"Serum and Brain Levels of 5-5-Diphenylbarbituric Acid (DPB) After Administration of dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) in the Rat," Epilepsia, 37:Supp. 5, p. 23, Abstract 1.84 (1996).|
|18||*||Samour et al. DE1939787, (1970) (Abstract only).|
|19||Samour et al.: "Anticonvulsants. 1, Alkoxymethyl Derivatives of Barbiturates and Diphenylhydantoin"; Journal of Medicinal Chemistry, 1971, vol. 14, No. 3 pp. 187-189.|
|20||Sircar, "CLXXIII.-The Influence of Groups and Associated Rings on the Stability of Certain Heterocyclic Systems. Part II. The Substituted Succinimides"; Journal of the Chemical Society, May 1927, pp. 1252-1258.|
|21||*||Susumu Kamata, Nobuhiro Haga, Takeaki Matsui and Wataru Nagata, Studies of Antitumor-Active 5-Fluorouracil Derivatives. I. Systhesis of N-Phthalidyl 5-Fluorouracil Derivatives, Chemical And Pharmaceutical Bulletin, vol. 33, No. 8, 1985, pp. 3160-3175.|
|22||Tagmann et al; Helv. Chim. Acta 35, 1541-1549 (1952).|
|23||Thacker et al., "A Method for Determination of 5,5-Diphenylbarbituric Acid and Separation from 1,3-Dimethoxymethyl-5,5-Diphenylbarbituric Acid in Plasma by High Performance Liquid Chromatography," Journal of Chromatography B, 710:149-155 (1998).|
|24||The Merck Index; An Encyclopedia of Chemicals, Drugs, and Biologicals; Tenth Edition, Published by Merck & Co., Inc., Rahway, NJ, USA, 1983, p. 544, (entry 3697).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7538108||Jun 14, 2006||May 26, 2009||Rigel Pharmaceuticals, Inc.||Prodrugs of 2,4-pyrimidinediamine compounds and their uses|
|US7557210||Jan 31, 2003||Jul 7, 2009||Rigel Pharmaceuticals, Inc.||2,4-pyrimidinediamine compounds and their uses|
|US7563892||Oct 5, 2006||Jul 21, 2009||Rigel Pharmaceuticals, Inc.||Prodrugs of 2,4 pyrimidinediamine compounds and their uses|
|US7582648||Oct 5, 2006||Sep 1, 2009||Rigel Pharmaceuticals, Inc.||Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds|
|US7683071||Aug 10, 2005||Mar 23, 2010||Taro Pharmaceuticals Industries Ltd.||Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid|
|US7723346||Feb 16, 2006||May 25, 2010||Taro Pharmaceutical Industries Ltd.||Non-sedating barbiturate compounds as neuroprotective agents|
|US7776871||Feb 16, 2006||Aug 17, 2010||Taro Pharmaceutical Industries Ltd.||Method of treating movement disorders using barbituric acid derivatives|
|US7906644||Oct 5, 2006||Mar 15, 2011||Rigel Pharmaceuticals, Inc.||2,4-pyrimidinediamine compounds and their uses|
|US7989448||Nov 10, 2008||Aug 2, 2011||Rigel Pharmaceuticals, Inc.||Prodrugs of 2,4-pyrimidinediamine compounds and their uses|
|US8076346||Jan 19, 2010||Dec 13, 2011||Taro Pharamaceutical Industries Ltd.||Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid|
|US8158639||Apr 13, 2010||Apr 17, 2012||Taro Pharmaceutical Industries Ltd.||Non-sedating barbiturate compounds as neuroprotective agents|
|US8178671||Jul 30, 2004||May 15, 2012||Rigel Pharmaceuticals, Inc.||Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds|
|US8211888||Jun 30, 2011||Jul 3, 2012||Rigel Pharmaceuticals, Inc.||Prodrugs of 2,4-pyrimidinediamine compounds and their uses|
|US8211889||Jan 12, 2012||Jul 3, 2012||Rigel Pharmaceuticals, Inc.||Prodrugs of 2,4-pyrimidinediamine compounds and their uses|
|US8314115||Dec 15, 2009||Nov 20, 2012||Taro Pharmaceutical Industries Limited||Method of treating movement disorders using barbituric acid derivatives|
|US8476263||May 18, 2012||Jul 2, 2013||Rigel Pharmaceuticals, Inc.||Prodrugs of 2,4-pyrimidinediamine compounds and their uses|
|US8785437||Jun 4, 2013||Jul 22, 2014||Rigel Pharmaceuticals, Inc.||Prodrugs of 2,4-pyrimidinediamine compounds and their uses|
|US8835430||Sep 26, 2013||Sep 16, 2014||Rigel Pharmaceuticals, Inc.||2,4-pyrimidinediamine compounds and their uses|
|US9018204||Jan 12, 2015||Apr 28, 2015||Rigel Pharmaceuticals, Inc.||2,4-pyrimidinediamine compounds and their uses|
|US20040029902 *||Jan 31, 2003||Feb 12, 2004||Rajinder Singh||2,4-Pyrimidinediamine compounds and their uses|
|US20040224947 *||Jun 10, 2004||Nov 11, 2004||Moros Daniel A.||Non-sedating barbiturate compounds as neuroprotective agents|
|US20050234049 *||Jul 30, 2004||Oct 20, 2005||Rajinder Singh||Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds|
|US20060035915 *||Jun 28, 2005||Feb 16, 2006||Taro Pharmaceutical Industries, Ltd.||Non-sedating barbituric acid derivatives|
|US20060122208 *||Aug 10, 2005||Jun 8, 2006||Daniella Gutman||Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid|
|US20060205747 *||Feb 16, 2006||Sep 14, 2006||Moros Daniel A||Non-sedating barbiturate compounds as neuroprotective agents|
|US20060234983 *||Jun 14, 2006||Oct 19, 2006||Rigel Pharmaceuticals, Inc.||Prodrugs of 2,4-pyrimidinediamine compounds and their uses|
|WO2012058216A2||Oct 25, 2011||May 3, 2012||The Gillette Company||Composition dispensing device comprising a non-foaming hydrating composition|
|WO2013025772A2||Aug 15, 2012||Feb 21, 2013||The Gillette Company||Composition dispensing device comprising a moisturizing composition|
|U.S. Classification||514/270, 544/302, 546/243, 514/391, 546/216, 514/425, 548/547, 514/328, 548/545, 548/317.1|
|International Classification||A61P25/00, C07D239/62, A61P25/08, C07C275/48, C07C231/08, C07C273/18, C07D233/74, C07D207/408, C07D263/44, C07D207/40, A61K31/496, C07C233/90, A61K31/515, C07D211/88|
|Cooperative Classification||C07D207/40, C07D263/44, C07D233/74, C07D207/408, C07D211/88, C07D239/62|
|European Classification||C07D207/40, C07D233/74, C07D211/88, C07D239/62, C07D207/408, C07D263/44|
|Jan 14, 2008||FPAY||Fee payment|
Year of fee payment: 8
|Jan 20, 2012||FPAY||Fee payment|
Year of fee payment: 12